Stem Cell Treatment

The bill allows patients with serious chronic diseases or terminal illnesses to access experimental stem cell treatments. It also enables doctors to recommend these treatments and requires the health department to create rules outlining which conditions qualify for this access.

TN SB0152 is a senate bill in the Tennessee 114th General Assembly, sponsored by Mark Pody (R), currently “Engrossed” since March 31, 2025.

We track 9,160 Tennessee bills this session, 182 of them sponsored by Mark Pody.

Supporters of the bill argue that it opens up new possibilities for patients suffering from debilitating conditions, giving them hope for innovative treatments that could improve their quality of life. They believe it empowers physicians to explore cutting-edge medical options that may not be widely available.

Critics of the bill express concern that it may lead to unregulated and potentially unsafe treatments being offered to vulnerable patients. They worry that the lack of rigorous oversight could result in exploitation of patients seeking desperate solutions for their health issues.

The analysis of Senator Mark Pody's personal financial interests in relation to Bill SB0152, which authorizes investigational stem cell treatments, reveals no direct overlaps that would suggest a significant conflict of interest. While Senator Pody is an insurance agent and owns a business, Pody & Associates, these interests do not directly intersect with the health care costs or pharmaceutical industries that the bill impacts. The bill primarily facilitates access to stem cell treatments for patients with severe chronic diseases or terminal illnesses, which does not appear to provide a financial benefit to Pody's insurance-related activities or other business interests.

Additionally, Pody's involvement in various estates and real estate does not correlate with the specific medical and health care implications of this bill. Given that there are no documented financial interests that would lead to personal gain from the passage of this legislation, the risk of conflict is assessed as low. Therefore, while the bill addresses significant health care issues, it does not pose a personal financial risk for the sponsor based on the information available.

Unlike federal analysis based on campaign donations, state analysis examines legislators' personal financial interests — their jobs, businesses, and investments.

Items marked "AI-researched" are generated from public sources but have not been independently verified. Verified data is sourced from official legislature websites and disclosure filings.